Rising Prevalence of Diabetes among People Boosts Global Insulin Market


Published Date : May 24, 2016

The insulin market is rapidly growing due to the rising incidences of diabetes. Diabetes results in an increase in the blood glucose level, which in turn causes various life threatening diseases. Insulin is thus used to metabolize the blood sugar. Demand for premixed and long-acting insulin derivatives is growing owing to the rising incidences of type 1 diabetes. 

According to a market intelligent company called Transparency Market Research (TMR), the global and China insulin market in is expected to rise at a 6.1% CAGR between 2013 and 2019. The market which was valued at US$19.99 bn in 2012, is expected to reach US$32.24 bn by 2019. 

According to the WHO, more than 366 mn people across the globe were diagnosed with diabetes in 2011 and an additional 280 mn people are extimated to be diagnosed with diabetes in the next two decades. 

Long-lasting Insulin to Expand at 8.7% CAGR from 2013 to 2019

The global and China insulin market is segmented by mode of action into long-acting, rapid-acting, short-acting, intermediate-acting, and premixed. Of these, the long-acting insulin segment is highly in demand due to their advantages such as need for smaller doses as compared to other derivatives, Moreover, the absence of strict regulations, price capping, and a robust pipeline is expected to promote the growth of the market. The rapid-acting insulin followed the long-lasting insulin derivatives. 

The insulin market is rapidly growing due to the rising incidences of diabetes. Diabetes results in an increase in the blood glucose level, which in turn causes various life threatening diseases. Insulin is thus used to metabolize the blood sugar. Demand for premixed and long-acting insulin derivatives is growing owing to the rising incidences of type 1 diabetes. 

According to a market intelligent company called Transparency Market Research (TMR), the global and China insulin market in is expected to rise at a 6.1% CAGR between 2013 and 2019. The market which was valued at US$19.99 bn in 2012, is expected to reach US$32.24 bn by 2019. 

According to the WHO, more than 366 mn people across the globe were diagnosed with diabetes in 2011 and an additional 280 mn people are extimated to be diagnosed with diabetes in the next two decades. 

Long-lasting Insulin to Expand at 8.7% CAGR from 2013 to 2019

The global and China insulin market is segmented by mode of action into long-acting, rapid-acting, short-acting, intermediate-acting, and premixed. Of these, the long-acting insulin segment is highly in demand due to their advantages such as need for smaller doses as compared to other derivatives, Moreover, the absence of strict regulations, price capping, and a robust pipeline is expected to promote the growth of the market. The rapid-acting insulin followed the long-lasting insulin derivatives. 

Growing Inclination towards the Use of Insulin to treat Diabetes to boost Insulin Market

The changing lifestyle and dietary habits of people is leading to an increase in the prevalence of diabetes. This is benefitting the insulin market. Furthermore, high entry barriers for biosimilar manufacturers is also boosting the insulin market. On the other hand, the growing acceptance of SGLT2 and GLP-1 among type 2 diabetes patients is expected to restrain the insulin therapy market. High cost is also expected to curb the growth of the insulin market. 

The changing lifestyle and dietary habits of people is leading to an increase in the prevalence of diabetes. This is benefitting the insulin market. Furthermore, high entry barriers for biosimilar manufacturers is also boosting the insulin market. On the other hand, the growing acceptance of SGLT2 and GLP-1 among type 2 diabetes patients is expected to restrain the insulin therapy market. High cost is also expected to curb the growth of the insulin market.